We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

The embedded finance company, which posted a loss last year, hired Citigroup to explore its strategic options and named an ...

Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Agenus in a report issued ...

William Blair cut their Q2 2026 earnings per share estimates for shares of Oracle in a report issued on Tuesday, March 11th.

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...